10-K/A: Precigen Files Amended 10-K to Include Omitted Part III Information

Precigen, Inc. has filed an amendment to its annual report on Form 10-K to include information previously omitted from Part III, related to directors, executive officers, and corporate governance.

Summary

• Precigen, Inc. filed an amendment to its annual report on Form 10-K to include information required by Part III, which was previously omitted.
• The original Form 10-K was filed on March 19, 2024, and this amendment is being filed because the company will not file a definitive proxy statement containing the Part III information within 120 days after the fiscal year-end.
• This amendment includes revisions to Part III, Items 10 through 14, and the Exhibit Index of the original Form 10-K.
• The amendment does not reflect events occurring after the filing of the original Form 10-K or modify disclosures affected by subsequent events, other than as expressly indicated.
• The document includes details about the company's directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.

Sentiment

Score: 7

Explanation: The document is primarily factual and descriptive, with a focus on corporate governance and compensation. The sentiment is neutral to slightly positive, as the company is taking steps to ensure compliance and align executive interests with shareholders.

Positives

• The company has a strong focus on corporate governance, with independent directors on key committees.
• The compensation program is designed to align executive interests with shareholder value creation.
• The company has a compensation recovery policy in place to address potential accounting errors.
• The company has a clear policy for related person transactions, ensuring fair dealings.
• The company has stock ownership guidelines for directors to align their interests with shareholders.

Negatives

• The company had to file an amendment to its annual report due to an omission of required information.
• The company's compensation program includes a significant portion of at-risk compensation, which could be a negative if performance goals are not met.
• The company's CEO pay ratio is 31 to 1, which may be a concern for some investors.

Risks

• The company's compensation program is subject to risks related to performance and market conditions.
• The company's reliance on equity awards could be a risk if the stock price declines.
• The company's related person transactions could pose a risk if not properly managed.
• The company's compensation recovery policy could be a risk for executives if there are accounting errors.

Future Outlook

The Compensation Committee is committed to continually reviewing and refining the company's executive compensation programs, with a focus on ensuring alignment with the company's overall strategy and shareholder interests and enhancing and promoting its pay for performance philosophy.

Management Comments

• The Compensation Committee believes that the most effective compensation program is one that provides competitive base pay, rewards the achievement of established annual and long-term goals and objectives, and provides incentives for retention.
• The Compensation Committee believes that significant ownership of our common stock by senior management helps to align the interests of management and the shareholders.

Industry Context

The document provides insight into the compensation practices of a biotechnology company, which is useful for understanding industry standards and trends in executive pay and corporate governance. The peer group analysis provides a benchmark for comparison with other similar companies in the sector.

Comparison to Industry Standards

• The company's peer group consists of 21 U.S.-based biotechnology companies, predominantly in Phase I/II clinical trials, with market capitalizations between $100 million and $1.4 billion.
• The peer group companies generally specialize in oncology, gene and/or cell therapy, vaccine development, or have a diverse portfolio with one or more of these specialties.
• The company's revenue of $22.1 million is at the 51st percentile of its peer group, while its market capitalization of $366 million is at the 46th percentile.
• The company's annualized 3-year total shareholder return (TSR) of -32% is at the 65th percentile of its peer group, indicating a relatively better performance compared to its peers.
• The company's compensation practices are benchmarked against this peer group to ensure competitiveness and alignment with industry standards.

Related Party Transactions

• An affiliate of Mr. Kirk purchased 11.4 million shares in a public offering for approximately $20.0 million.
• J.P. Morgan Securities LLC, where Mr. Frank serves as Chairman of Global Healthcare Investment Banking, received underwriting commissions of $2.56 million for the public offering.
• The company had transactions with Intrexon Energy Partners and Intrexon Energy Partners II, joint ventures where the company had a 50% membership interest.

Stakeholder Impact

• Shareholders are impacted by the company's compensation practices and corporate governance policies.
• Employees are impacted by the company's compensation and benefit programs.
• Customers and suppliers are not directly impacted by the information in this document.

Next Steps

• The company will continue to monitor and refine its executive compensation programs.
• The company will continue to monitor certain compensation practices at a variety of similarly situated or similarly structured companies in assessing and making compensation decisions going forward.
• The company will continue to consider the outcome of the say-on-pay vote for future compensation decisions for its executive officers.

Key Dates

Keywords

executive compensation, corporate governance, board of directors, financial reporting, stock options, restricted stock units, audit committee, compensation committee, related party transactions, director independence